Peptides
Phase 1Biologic
Peptides is one of 70 biologic programs targeting Melanoma. It is currently in Phase 1.
2
Indications
4
Total Trials
1
Active Trials
69
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Single Dose of
Boehringer IngelheimPhase 3
Interferon-Gamma
SSPP Pharmaclon Ltd.
Phase 3
GSK2118436
GSKPhase 3
IBI308
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
Cancervax Vaccine (CANVAXIN)
CCancerVax Corporation
Phase 3
Intron a
Merck & Co.Preclinical
Opdualag
Bristol-Myers SquibbPreclinical
PEG-Intron
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Glioblastoma1 trial
Melanoma1 trial
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Completed·—·Phase 1·NCT01970358·15 enrolled
Immunogenicity1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Peptides. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details